Livzon Pharmaceutical Group Inc. (Livzon Pharma) has convened a Board meeting for 8 September 2026 to deliberate on the potential declaration and distribution of a special dividend.

The company stated that a follow-up announcement will be issued after the meeting to disclose the specific terms of the proposed payout, should it receive Board approval. Until a final decision is confirmed, Livzon Pharma advises shareholders and prospective investors to exercise caution when dealing in its securities.

As at 27 August 2026, the Board comprises two executive directors—Liu Daping (President) and Tang Yanggang (Vice Chairman); three non-executive directors—Zhu Baoguo (Chairman), Lin Nanqi and Qiu Qingfeng; one employee representative director—Ran Yongmei; and four independent non-executive directors—Luo Huiyuan, Cui Lijie, Wang Zhiyao and Kang Li.

The company secretary is Liu Ning, and the announcement was released from Zhuhai, China. No further financial figures or distribution parameters were provided in the disclosure.